FDA Approves First Oral Drug for Dermatomyositis in Adults
The FDA approved Lisraya (brepocitinib) tablets for treatment of dermatomyositis in adults. The approval is a final agency decision. It grants an oral JAK/…
Impact analysis · 55/100 · AI-assisted priority
This score prioritizes research; it does not predict an outcome. Method and limitations.
What happened
The FDA approved Lisraya (brepocitinib) tablets for treatment of dermatomyositis in adults. The approval is a final agency decision. It grants an oral JAK/TYK2 inhibitor for a rare autoimmune disease with Orphan Drug and Priority Review designations.
Quantitative evidence
- 241 adult patients randomized in phase 3 trial
- 52‑week treatment duration
- 6% discontinuation due to adverse reactions on 30 mg vs 11% on placebo
- Exact effect size of TIS score
- Statistical significance values
Affected entities
Analysis
The following contextual analysis is AI-assisted and separated from the reported primary-source record above.
Scientific context
The drug is a first‑in‑class oral JAK/TYK2 inhibitor offering a new mechanism against dermatomyositis.
Market context
The approval opens up a market for a rare disease with limited therapeutic options, potentially giving Priovant a niche positioning.
Legal and regulatory context
This is a final FDA approval granting market authorization under Orphan Drug and Priority Review programs.
Sources
For informational use only. Verify decisions against the linked regulator or primary source.
Evidence & limits
Source: Open the source record
- Record identifier
- 2f11a8e15afeaec3e6ebd775931d18512de0d85463079673df4a7ad033779c2b
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- 2026-08-27T213011Z
What it supports. The linked authority’s action, within the product, indication, jurisdiction, and procedural stage stated in that record.
Limits. A committee opinion, draft, or announcement does not by itself establish final authorization. The summary and contextual analysis are AI-assisted; a source link does not establish human review.
Connection basis. Related profiles are normalized name mentions in article text. A mention does not establish a legal relationship.